<DOC>
	<DOCNO>NCT02381314</DOCNO>
	<brief_summary>The purpose study evaluate safety enoblituzumab ( MGA271 ) combination Yervoy ( ipilimumab ) give patient B7-H3-expressing melanoma , squamous cell carcinoma head neck ( SCCHN ) , non small cell lung cancer ( NSCLC ) B7H3 express cancer . The study also evaluate best dose enoblituzumab use give ipilimumab . Assessments also do see drug act body ( pharmacokinetics ( PK ) , pharmacodynamics ) evaluate potential anti-tumor activity enoblituzumab combination ipilimumab .</brief_summary>
	<brief_title>Safety Study Enoblituzumab ( MGA271 ) Combination With Ipilimumab Refractory Cancer</brief_title>
	<detailed_description>This study Phase 1 open-label , dose escalation , cohort expansion study enoblituzumab administer intravenously ( IV ) weekly schedule 51 dos combination IV ipilimumab administer every-3-week schedule 4 dos . The dose escalation phase design characterize safety tolerability combination enoblituzumab ipilimumab define maximum tolerate administer dose ( MTD/MAD ) patient B7-H3 express mesothelioma , urothelial cancer , NSCLC , SCCHN , Clear cell renal cell carcinoma ( ccRCC ) , ovarian cancer , melanoma , thyroid cancer , Triple negative breast cancer ( TNBC ) , pancreatic cancer , colon cancer , soft tissue sarcoma , prostate cancer . The cohort expansion phase , 3 cohort 16 patient enrolled evaluate safety potential efficacy combination administer MTD/MAD dose patient melanoma , NSCLC , SCCHN . All tumor evaluation carry Response Evaluation Criteria Solid Tumors ( RECIST ) immune-related response criterion ( irRC ) .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologicallyproven , unresectable , locally advanced metastatic melanoma , SCCHN , NSCLC express B7H3 . Melanoma progress within 90 day progression checkpoint inhibitor ( e.g. , antiPDL1 , antiPD1 , antiCTLA4 ) recent prior therapy SCHNN NSCLC progress follow 1 5 prior systemic regimen Mesothelioma progress follow least 1 3 prior systemic treatment unresectable locally advanced metastatic disease . The prior systemic chemotherapy must include pemetrexed ( antifolate ) base regimen combination platinum agent . For patient pemetrexed contraindicate tolerated approved therapy ( e.g. , peritoneal mesothelioma ) , prior therapy firstline platinumbased regimen require . Urothelial cancer arise bladder , renal pelvis , ureter urethra progress follow least 1 5 prior systemic treatment unresectable locally advanced metastatic disease ( include antiPDL1 , antiPD1 , exclude experimental therapy ) . Patients must receive least one platinumcontaining regimen ( e.g. , gemcitabine/cisplatin [ GC ] , dosedense methotrexate/vinblastine/doxorubicin/cisplatin [ DDMVAC ] , carboplatinum/gemcitabine ) . No 5 prior systemic regimen allow . Thyroid cancer progress follow least 1 5 prior chemotherapy regimen ( ) . Prior therapy exclude experimental therapy give Phase 1 trial . Pancreatic cancer progress follow least 1 3 prior chemotherapy regimen . Prior therapy exclude experimental therapy give Phase 1 trial . Ovarian cancer progress follow least 2 4 prior therapeutic regimen ( e.g. , 2 prior platinum contain regimen platinum resistant , liposomal doxorubicin topotecan contain regimen ) . Prior therapy exclude experimental therapy give Phase 1 trial Colon cancer progress follow least 2 4 prior therapeutic regimen ( e.g. , fluoropyrimidine and/or irinotecan and/or oxaliplatin and/or antiEGFR antibody contain regimen ) . Prior therapy exclude experimental therapy give Phase 1 trial . Prostate cancer progress follow least 1 5 prior therapeutic regimen ( e.g. , abiraterone , enzalutamide , docetaxel ) . Prior therapy exclude experimental therapy give Phase 1 trial . Soft tissue sarcoma progress follow least 1 5 prior therapeutic regimen . Prior therapy exclude experimental therapy give Phase 1 trial . TNBC progress follow least 1 5 prior therapeutic regimen . Prior therapy exclude experimental therapy give Phase 1 trial . ccRCC progress follow least 1 5 prior therapeutic regimen . Prior therapy exclude experimental therapy give Phase 1 trial . Measurable disease per RECIST 1.1 criterion ECOG performance status 0 1 Acceptable laboratory parameter adequate organ reserve . Patients history symptomatic central nervous system metastasis , unless treat asymptomatic Patients history autoimmune disease certain exception History allogeneic bone marrow , stem cell , solid organ transplant Treatment systemic cancer therapy investigational therapy within 4 week ; radiation within 2 week ; trauma major surgery within 4 week History clinicallysignificant cardiovascular disease ; gastrointestinal perforation ; gastrointestinal bleeding , acute pancreatitis diverticulitis within 4 week ; Active viral , bacterial , systemic fungal infection require parenteral treatment within 7 day ; positive human immunodeficiency virus AIDS , hepatitis B C. Known hypersensitivity recombinant protein , polysorbate 80 , excipient contain drug vehicle formulation MGA271 ipilimumab .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>B7-H3-expressing neoplasm</keyword>
</DOC>